Pear Therapeutics, Sandoz ink deal for prescription digital therapeutics

Pear Therapeutics revealed yesterday that it agreed to deal commercialization rights of its digital therapeutics to Novartis (NYSE:NVS) division Sandoz.
The company’s reSET substance use disorder therapy became the first prescription digital therapeutic approved by the FDA in September last year. reSET-O, a digital therapeutic designed for people suffering from opioid use disorder, is under review at the FDA.
Get the full story at our sister site, Drug Delivery Business News.
The post Pear Therapeutics, Sandoz ink deal for prescription digital therapeutics appeared first on MassDevice.

Source: Mass Device - April 19, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Patient Monitoring Wall Street Beat Novartis peartherapeutics sandoz Source Type: news